Bristol Myers-Pfizer Alliance launch collaboration with Mark Cuban for Eliquis

The Bristol Myers Squibb-Pfizer (BMY) – Pfizer (PFE) Alliance announced the launch of a collaboration with Mark Cuban Cost Plus Drug Company to offer Eliquis, or apixaban, on CostPlusDrugs.com. Eliquis is one of the most widely prescribed oral anticoagulants in the United States and one of the largest brands in the space to be offered on the site, which allows patients to purchase prescription medicines directly at reduced costs, providing another avenue for patients to access the medication. Beginning April 27, 2026, Eliquis will be available on Cost Plus Drugs, and patients with a prescription will pay a total of $345 for a 30-day supply. Teaming up with Cost Plus Drugs provides another option for cash-paying patients to access Eliquis directly. Eliquis is an important treatment option for patients with atrial fibrillation, or AFib, not caused by a heart valve problem, to reduce the risk of stroke and blood clots, as well as to treat blood clots in the veins of the legs or lungs and reduce the risk of them recurring. For every 100,000 patients treated, Eliquis has resulted in an estimated $3B in total healthcare cost savings and avoidance, such as hospitalization and extended rehabilitation needs.